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Abstract
Background. Vascular calciﬁcation (VC), mainly due to
elevated phosphate levels, is one major problem in patients
sufferingfromchronickidneydisease.Inclinicalstudies,an
inverse relationship between serum magnesium and VC has
beenreported.However,thereisonlyfewinformationabout
the inﬂuence of magnesium on calciﬁcation on a cellular
levelavailable.Therefore,weinvestigatedtheeffectofmag-
nesium on calciﬁcation induced by b-glycerophosphate
(BGP) in bovine vascular smooth muscle cells (BVSMCs).
Methods. BVSMCs were incubated with calciﬁcation media
for 14 days while simultaneously increasing the magnesium
concentration. Calcium deposition, transdifferentiation of
cells and apoptosis were measured applying quantiﬁcation
of calcium, von Kossa and Alizarin red staining, real-time
reverse transcription–polymerase chain reaction and annexin
V staining, respectively.
Results. Calcium deposition in the cells dramatically in-
creased with addition of BGP and could be mostly pre-
vented by co-incubation with magnesium. Higher
magnesium levels led to inhibition of BGP-induced alkaline
phosphatase activity as well as to a decreased expression of
genes associated with the process of transdifferentiation of
BVSMCs into osteoblast-like cells. Furthermore, estimated
calcium entry into the cells decreased with increasing mag-
nesium concentrations in the media. In addition, higher
magnesium concentrations prevented cell damage (apopto-
sis) induced by BGP as well as progression of already
established calciﬁcation.
Conclusions. Higher magnesium levels prevented BVSMC
calciﬁcation, inhibited expression of osteogenic proteins,
apoptosis and further progression of already established
calciﬁcation. Thus, magnesium is inﬂuencing molecular
processes associated with VC and may have the potential
to play a role for VC also in clinical situations.
Keywords: apoptosis; magnesium; phosphate; vascular calciﬁcation;
vascular smooth muscle cells
Introduction
Vascular calciﬁcation (VC) is common in patients suffering
from chronic kidney disease (CKD) and has a progressive
nature which eventually leads to increased mortality rates
compared to the general population [1, 2]. It has been
shown that VC is not only due to passive precipitation of
calcium phosphate but rather resembles an active process
involving transdifferentiation of vascular smooth muscle
cells (VSMCs) into osteoblast-like cells, including changes
in the expression of bone-associated and mineralization-
regulating proteins as well as apoptosis [3, 4]. However,
the underlying pathophysiologic mechanisms are poorly
understood. It is proposed that along with traditional
cardiovascular risk factors, non-traditional risk factors,
such as those related to uraemic status and a disturbed bone
and mineral metabolism, may play a role in the increased
prevalence of VC and cardiovascular disease in CKD
patients.
Magnesium, in addition to its involvement in the func-
tions of many enzymes, plays a role in skeletal and mineral
metabolism and vascular tone. Recently, data from obser-
vational clinical studies suggested that serum magnesium
concentrations are inversely related with the presence of
VC or atherosclerosis [5, 6] and also with cardiovascular
and all-cause mortality in uraemic as well as non-uraemic
populations [7–9]. However, so far, only a limited number
of experimental studies, mostly performed in animals have
conﬁrmed these ﬁndings, whereas the majority investigated
the role of lowering dietary magnesium on VC [10–12]. To
date, only one group has investigated the role of magne-
sium in an in vitro model in a prechondrogenic cell line and
reported a favourable effect of magnesium on bone matrix
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calciﬁcation has not yet been studied in in vitro models.
Therefore, the aim of the present study was to investigate
whether increasing magnesium concentrations have effects
on calciﬁcation of bovine vascular smooth muscle cells
(BVSMCs).
Materials and methods
Cell culture
BVSMCs were purchased from Corriell Cell Repositories and were used
between Passages 2 and 8. Cells were cultured in glucose Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (0.9 mM P, 1.8 mM Ca
21, 0.8 mM
MgSO4) supplemented with 10% fetal bovine serum (FBS). After addition
of FBS, Mg concentration was measured to be 1.0 mM.
Calciﬁcation assay
BVSMC calciﬁcation was induced as previously described [14]. Brieﬂy,
0.6 3 10
4 cells per well (6-well format) were incubated for 7–14 days with
high-glucose DMEM, supplemented with 15% FBS, 10 mM b-glycero-
phosphate (BGP), 50 mg/mL ascorbic acid, 10
 7 mol/L insulin, 10 mmol/
L sodium pyruvate and 10 000 units/mL penicillin G, 10 mg/mL strepto-
mycin sulphate and 25 lg/mL amphotericin B (v/v 1:100) (calciﬁcation
media). MgCl2 was added to reach ﬁnal Mg
21 concentrations of 2 and
3 mM. Control medium was prepared equally but without BGP.
Quantiﬁcation of calcium deposition
BVSMCs were decalciﬁed with 0.6N HCl for 24 h at the time point
indicated and calcium content of the supernatants was determined by
o-cresolphthalein complexmethod (Calciumkit; Pointe Scientiﬁc, Canton,
MI). Calcium content was normalized to the protein content using BCA
protein assay kit (Pierce, Rockford, IL).
Alkaline phosphatase (ALP) activity
Alkaline phosphatase (ALP) activity was quantiﬁed using a commercially
available kit (Pointe Scientiﬁc) according to the manufacturer’s protocol.
Protein concentrations were quantiﬁed using BCA protein assay kit and
ALP activity was normalized for cellular protein content.
Von Kossa and Alizarin red staining
Nodules were ﬁxed in 10% buffered neutral formalin phosphate for 24 h at
4 C, washed, incubated with 5% silver nitrate solution for 30–90 min and
exposed to 5% sodium thiosulphate for 2 min. Counterstaining was
performed in 2 mL nuclear fast red. For Alizarin red staining, cells were
incubated with 10% neutral buffered formalin for 15 min, rinsed and
incubated with a 2% aqueous Alizarin red solution (pH 4.0–4.2) for
10–15 min.
Real-time reverse transcription–polymerase chain reaction
The quantiﬁcation of selected transcripts was performed using real-time
TaqMan  PCR technology. Complementary DNA (cDNA) was synthe-
sizedfrom 2lgof RNA usinga commercially availablekit (High Capacity
cDNA Archive Kit; Applied Biosystems Inc., Foster City, CA) according
to the manufacturer’s instructions. Quadruplicate real-time TaqMan  pol-
ymerase chain reactions (PCR) was carried out with the ABI Prism
7900HT Sequence Detector System (Applied Biosystems) using cDNA
equivalent to 5 ng of RNA with speciﬁc real-time PCR assays (Assays-
on-Demand Gene Expression System; Applied Biosystems). Expression
levels were determined applying the comparative threshold cycle (DCt)
method using glyceraldehyde-3-phosphate dehydrogenase as endogenous
control.
Enzyme-linked immunosorbent assay measurements
After 14 days of incubation with the indicated media, supernatants of the
cells were stored at  80 C. ELISA kit for Matrix-Gla protein (MGP) was
purchased from Biomedica (Vienna, Austria), for bone morphogenetic pro-
tein 2 (BMP2) from R&D Systems (Minneapolis, MN) and measurements
were performed according to the manufacturer’s protocol. Media calcium,
phosphorus and magnesium were determined by standard biochemical
methods using an autoanalyzer (Architect c16000; Abbott Diagnostics,
Abbott Park, IL).
Western blot analysis
BVSMCs were incubated with calciﬁcation media in a 6-well format for
14 days. Cells were lysed in a buffer containing 20 mM Tris–HCl, 2 mM
ethyleneglycoltetraacetic acid, 5 mM ethylenediaminetetraacetic acid and
80 lg of total protein was fractioned by 12% sodium dodecyl sulphate–
polyacrylamidegelelectrophoresisandelectro-transferredtonitrocellulose
membranes. The membranes were blocked with Tris-buffered saline (pH
7.4)/5% skimmed milk powder/0.1% Tween and incubated with the indi-
cated antibodies according to the manufacturer’s protocol. Horseradish
peroxidase (HRP)-labelled antibodies were visualized with enhanced
chemiluminescencedetectionsystem(AmershamBiosciences,Piscataway,
NJ) on standard X-ray ﬁlm. After scanning of the ﬁlms, software-aided
densitometric analysis was performed (ImageQuant TL v2005; Amersham
Biosciences). Runx2 (M-70) antibody was from Santa Cruz (Santa Cruz
BiotechnologyInc.,CA)andb-actinantibodyandHRP-labelledsecondary
antibody from Sigma–Aldrich (St Louis, MO).
Apoptosis and cell viability
The percentage of apoptotic cells was determined by incubating BVSMCs
under the indicated conditions and performing annexin V-FITC staining
according to the manufacturer’s protocol (Becton Dickinson, Franklin
Lakes, NJ). Cell viability was assessed by Celltiter 96 Aqueous One Cell
Proliferation Assay (Promega, Madison, WI).
Statistical analysis
Means of more than two variables were compared by performing an analysis
of variance. In the case of signiﬁcant difference in means of more than two
variables, means of all groups were compared pairwise adjusting the alpha
according to the method of Bonferroni to correct for multiple testing.
Results
The aim of this study was to determine the effect of magne-
siumoncalciﬁcationina cellculture modelinorder toreveal
mechanisms underlying the above described positive effects
of magnesium on cardiovascular parameters. Therefore, the
inﬂuence of different medium magnesium levels on BGP-
induced calciﬁcation was assessed in BVSMCs. Read outs
were tissue content of calcium as well as other molecular
markers, known to be involved in the progression of VC.
BGP-induced deposition of calcium in BVSMCs
The addition of BGP to the culture media induces high
phosphate levels and the deposition of calcium in VSMCs
[15]. Concordantly, we could observe a strong accumulation
of calcium after incubation of BVSMCs for 7 days with
10 mM BGP (Figure 1A). The medium concentration of
1.1 mM magnesium matches the normal serum magnesium
concentrationsincattleaswellasinhumans. Toevaluatethe
effectofmagnesiumonBVSMCcalciﬁcation,theamountof
calcium per mg protein was quantiﬁed in the presence of
BGP as well as with increasing magnesium concentrations.
Higher magnesium concentrations led to a strong reduction
of calcium content in the cells compared to BGP alone. This
inhibitory effect of magnesium was even more pronounced
after a cultivation period of 21 days, showing a reduction of
calcium content in the presence of 2 mM magnesium by
76% (Figure 1B). To test whether the progression of already
established calciﬁcation could be prevented, magnesium
was added to the cells 7 and 14 days after initiation of
calciﬁcation with BGP (Figure 1C). Addition of magnesium
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lular calcium. At day 14, cells incubated with BGP and
magnesium showed a signiﬁcant inhibition compared to in-
cubation with BGP alone. Further incubation with magne-
sium (until day 14, measured 21 days after initiation of
calciﬁcation) even led to a slight but signiﬁcant reduction
compared to measurement on day 14. Addition of magne-
sium at day 14 of calciﬁcation still inhibited progression and
measurement on day 21 showed that the established calciﬁ-
cation of day 14 was signiﬁcantly reduced.
The inhibition of calcium deposition by elevated extrac-
ellular magnesium concentrations could be conﬁrmed in
von Kossa and Alizarin red stainings (Figure 1D and E).
Markers of transdifferentiation into osteoblast-like cells
It has been shown that VC is not only a passive process due
to an elevated calcium phosphate product. The pathophy-
siological mechanisms also include active processes like
the transdifferentiation of BVSMCs into osteoblast-like
cells, which are then capable of producing extracellular
matrix components normally involved in bone formation
[3, 4]. To assess a possible inﬂuence of magnesium on the
formation of osteoblast-like cells, we investigated the ex-
pression of two transcription factors for osteoblastic differ-
entiation: CBFA1 and MSX2 as well as a chondrocyte
transcription factor SOX9 in the presence of normal and
elevated magnesium concentrations, respectively. As ex-
pected, CBFA1, MSX2 as well as SOX9 were induced in
the presence of BGP (Figure 2A and B). CBFA1 showed
2.13-fold expression in the presence of 10 mM BGP which
was strongly inhibited in the presence of 2 and 3 mM
magnesium. The concentration-dependent inhibition of
BGP-induced CBFA1 by magnesium was conﬁrmed on
protein level by western blot analysis (Figure 2D). BGP-
induced MSX2 up-regulation was restored to control levels
by incubation with 2 or 3 mM magnesium (Figure 2A). The
prominent induction of SOX9 by BGP was reduced in the
presence of 2 mM magnesium and nearly completely in-
hibited in the case of 3 mM magnesium (Figure 2B).
ALP expression and activity
ALP up-regulation has been shown to be involved in the
process of calciﬁcation of BVSMCs. In our experiments,
BGP led to an ~2-fold up-regulation of ALP expression
relative to control conditions (Figure 2A). This increase
was reduced with 2 and 3 mM magnesium by 52 and
66%, respectively. On a functional level, measured in terms
of enzyme activity, we observed an even stronger inhibi-
tory effect of magnesium (Figure 2C): elevating the mag-
nesium concentration to 2 mM led to a 79% reduction of
the BGP-induced increase in ALP activity and 3 mM ex-
tracellular magnesium even reduced ALP activity to levels
below control conditions.
Fig. 1. Effect of magnesium on BGP-induced deposition of calcium in
BVSMCs. BVSMCs were incubated for 7 days (A) and 21 days (B)u n d e r
calcifying conditions (110 mM BGP) either in the presence of physiolog-
ical (1.1 mM ¼ control) or elevated extracellular magnesium (2 and 3 mM).
Magnesium was added from start (A and B) or at the time points indicated
(C). Dashed lines in graph C indicate the presence of magnesium. Data are
given as means and SDof at least six replicates (a ¼ difference versus BGP:
P < 0.05, b ¼ difference versus same condition Day 14: P < 0.05). In
parallel, von Kossa (D) Alizarin red (E) staining was performed with cells
treated for 14 days under the same conditions as mentioned above.
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Under physiological conditions, there are various mecha-
nisms in BVSMCs to counteract the transdifferentiation into
osteoblast-like cells and the deposition of calcium in form of
hydroxyapatite crystals. MGP is one known inhibitor of
calciﬁcationandwasshowntobedown-regulatedincalciﬁed
vessels [16]. Incubating BVSMCs with BGP resulted in an
86% decrease of MGP secretion, while simultaneously
increasing the extracellular magnesium concentration nor-
malized the MGP secretion to control levels (Figure 3A).
Surprisingly, further addition of magnesium (3 mM) even
increasedMGPconcentrationsby68%abovenormalvalues.
MGP is known to mediate its action in part by binding
BMP2, thereby inhibiting its pro-calcifying actions [17].
BMP2 was increased in BVMCs after 7 days of incubation
with calciﬁcation media (Figure 3B). When co-incubating
the cells with 2 mM magnesium, we observed a restoration
to control levels and a further elevation to 3 mM magne-
sium led to strong reduction of BMP2 secretion to levels
below control.
Apoptosis and elevated phosphate concentrations
Apoptosis has been identiﬁed as an important contributor
to VC [18]. We therefore evaluated the effects of magne-
sium on BGP-induced apoptosis and on cell viability.
After 14 days of incubation, the addition of BGP doubled
the percentage of apoptotic BVSMCs compared to
physiological conditions (Figure 4A). Higher magne-
sium levels (2mM) during the calciﬁcation period
reduced this effect and in the case of 3 mM extracellular
magnesium led to levels of apoptosis similar to the
control group. The observed effects were reﬂected in cell
viability, which was reduced after incubation with the
phosphate source BGP and could be restored by the
addition of further magnesium to the cell culture media
(Figure 4B).
Extracellular magnesium concentrations and calcium
entry in BVSMCs
Most of the effects shown to be involved in the process of
calciﬁcation in BVSMCs were inﬂuenced by magnesium in
our experiments. Therefore, we evaluated the inﬂuence of
magnesium on calcium entry into the cells, a prerequisite for
calciﬁcation. To estimate the amounts of magnesium and
calcium taken up by BVSMCs, we measured the respective
concentration in the mediaafter an incubation period of 48 h
in the presence of increasing magnesium concentrations
(Tables 1 and 2). Calculating the difference to concentra-
tions present in the media before incubation with BVSMCs,
we estimated the total amount of magnesium and calcium
taken up by the cells (Table 1). Increasing extracellular
magnesium led to a dose-dependent increase in estimated
uptake of magnesium itself, while simultaneously decreas-
ing calcium entry into the cells (Table 2). This was true,
albeit the fact that calcium concentration at the beginning of
Fig. 2. EffectofmagnesiumonBGP-inducedexpressionofproteinsinvolved
in calciﬁcation in BVSMCs. BVSMCs were incubated for 14 days under
calcifying conditions either in the presence of physiological or elevated ex-
tracellular magnesium. ALP activity was quantiﬁed in cell lysates (C)a n d
normalized to the amount of protein. For western blot analysis equal amounts
ofproteinswerestainedforCBFA1>andß-actin(D).(A,BandC)datashown
are means and SD of eight replicates (a ¼ difference versus BGP: P < 0.05).
Fig. 3. Inﬂuence of magnesium on the secretion of proteins involved in
calciﬁcation. Protein concentrations of MGP and BMP2 were quantiﬁed in
the supernatants of BVSMCs by ELISA (A and B). Cells were incubated
for 14 days under calcifying conditions either in the presence of physio-
logical or elevated extracellular magnesium concentrations. Data shown
are means and SD of eight replicates (a ¼ difference versus BGP: P <
0.05; b ¼ difference versus control: P < 0.05).
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investigated.
Discussion
Previousclinicalandanimalstudiesinbothuraemicandnon-
uraemic conditions have shown an association of lower mag-
nesium levels with increased VC as well as a decreased risk
of peripheral VC with increased serum magnesium in non-
diabetic haemodialysis patients [12,15,19–21]. Furthermore,
magnesium supplementation reduced media intima thick-
ness in these patients [6]. Recently, elevated dietary mag-
nesium was shown to prevent tissue mineralization in an
animal model and low magnesium diet in a mouse model
for dystrophic cardiac calciﬁcation-induced marked car-
diac calciﬁcations [12, 22]. However, only few in vitro
studies providing mechanistic insight into the action of
magnesium on VC were performed so far. Our study, for
the ﬁrst time, provides in vitro evidence for the preventive
effect ofmagnesium oncalciﬁcationina cell culture model
of BVSMCs.
In the present study, we found that increasing magne-
sium concentrations in the media of BVSMCs strongly
inhibit BGP-induced calciﬁcation. This effect was dose-
dependent and stable over a period of up to 21 days. It
has been shown that magnesium is able to impair hydrox-
yapatite crystal growth in in vitro experiments and it has
been suggested that the effect of magnesium on VC and
atherosclerosis may be mediated via this mechanism [23–
25], which is supported by the decrease in calcium depo-
sition with increasing magnesium concentrations observed
in our experiments. In the present study, magnesium was
not only able to prevent BVSMC calciﬁcation but also to
inhibit progression of already established calciﬁcation.
With longer incubation time, magnesium even partly re-
verted calciﬁcation, which would be of great clinical im-
portance. Although CKD patients are treated with
phosphate binders in order to lower serum phosphorus con-
centrations, as one aspect of VC development, VC pro-
gresses overtime. Therefore, magnesium supplementation
or treatment with magnesium-containing phosphate binders
in CKD patients might be able to partially revert or at least
inhibit the progression of VC.
In addition to the role of deposition of calcium–phosphate
in terms of matrix mineralization, it is now well established
that VC is an active, cell-mediated process including apop-
tosis as well as the osteochondrogenic differentiation of
VSMCs showing similarities to bone formation [3, 4, 26].
The speciﬁc osteogenic transcription factor CBFA1
was shown to be up-regulated in VSMCs undergoing
phosphate-induced transdifferentiation into osteoblast-like
cells. Further genes like ALP, SOX9 and MSX2, normally
linked to calciﬁcation in osteoblasts, are up-regulated
by elevated phosphate concentrations in in vitro models
[14, 27]. This could be conﬁrmed in our model. The
enhanced expression of ALP, CBFA1, SOX9 and MSX2
induced by high phosphorus, decreased with higher mag-
nesium levels, clearly showing that the inhibitory effect of
magnesium on BVSMC calciﬁcation was not only true for
the deposition of calcium within the cells but also affected
the osteogenic transdifferentiation. Very recently, it has
been shown that nanocrystals are actively involved in the
process of calciﬁcation and rather than high phosphate con-
centrations alone are a prerequisite for the induction of
genes like BMP2 and osteocalcin [28, 29]. Therefore, also
the mentioned inhibitory inﬂuences of magnesium on crys-
tal formation, described in the literature, may be in part
responsible for the inhibitory effect of magnesium on trans-
differentiation into osteoblast-like cells, observed in our
Fig. 4. Effect of calciﬁcation on the induction of apoptosis and on cell
viability. To induce calciﬁcation, BVSMCs were incubated in the presence
of 10 mM BGP for 14 days. The inhibitory effect of magnesium was
assessed by raising the physiological magnesium concentration in the
media from 1.1 mM (control) to 2 and 3 mM. The percentage of apoptotic
cells (A) and cell viability (B) was quantiﬁed. Data shown are mean and
SD of 4 (A) and 3 (B) experiments (a ¼ difference versus BGP: P < 0.05).
Table 1. Estimated Mg uptake by BVSMCs during 48 h incubation
a
Initial
Mg [mM]
Mg after
48 h [mM]
D Mg
[mM]
D Mg
[nmol]
Control 1.1 0.77 6 0.02 0.33 6 0.02 0.66 6 0.05
BGP 1.1 0.75 6 0.06 0.35 6 0.06 0.69 6 0.12
12 mM Mg 2 0.84 6 0.12 1.16 6 0.12 2.23 6 0.24
13 mM Mg 3 1.62 6 0.14 1.38 6 0.14 2.76 6 0.29
aCalciﬁcation was induced in BVSMCs in the presence of physiological or
increasing magnesium concentrations for 14 days. Magnesium uptake was
estimated by calculating the differences of magnesium present in the media
before and after incubation for 48 h with fresh media containing the same
additives as before.
Table 2. Estimated Ca uptake by BVSMCs during 48 h incubation
a
Initial
Ca [mM]
Ca after
48 h [mM]
D Ca
[mM]
D Ca
[nmol]
Control 1.8 1.78 6 0.07 0.03 6 0.06 0.06 6 0.13
BGP 1.8 0.53 6 0.05 1.27 6 0.05 2.55 6 0.10
12 mM Mg 1.8 0.78 6 0.01 1.02 6 0.15 2.04 6 0.03
13 mM Mg 1.8 1.58 6 0.07 0.22 6 0.07 0.44 6 0.14
aCalciﬁcation was induced in BVSMCs in the presence of physiological or
increasing magnesium concentrations for 14 days. Ca uptake was esti-
mated by calculating the differences of magnesium present in the media
before and after incubation for 48 h.
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hibitory effect of magnesium on calciﬁcation will also ac-
count in the bone, as it has been shown that physiological
magnesium concentrations present in bone are not able to
inhibit crystal growth [24]. Our study suggests that magne-
sium inhibits the pathological transdifferentiation process
from VSMCs into osteoblast-like cells, which does not take
place in the physiological process of calciﬁcation in the
bone. However, detailed clinical investigations about the
effect of magnesium on bone metabolism, speciﬁcally in
renal failure patients, are rare and contradictory [32, 33].
Properly designed in vitro as well as clinical studies to
evaluate further the inﬂuence of magnesium on bone are
still needed.
The remaining calcium deposition, observed in our
experiments despite full inhibition of transdifferentiation
in terms of marker genes, is in concordance with addi-
tional processes involved in calciﬁcation as apoptosis
and matrix mineralization which were not fully inhibited
in our settings [34]. MGP, a locally produced inhibitor of
VC [35], which was signiﬁcantly decreased during calci-
fying conditions in our experiments was not only restored
to normal levels by magnesium but even strongly up-
regulated when high magnesium concentrations were
present. The inhibition is probably mediated by its capa-
bility to bind BMP2, which itself-via promotion of differ-
entiation of VSMCs into osteochondrocyte-like cells-
induces calciﬁcation [36]. Our ﬁnding that MGP levels
signiﬁcantly decreased when BVSMC calciﬁcation was
induced by BGP, conﬁrms the reported negative associa-
tion of MGP with VC.
Recently, it has been reported that apoptosis is also in-
volved in the process of VC and that elevated phosphate
levels induce apoptosis in a type III inorganic phosphate
transporter (Pit-1)-dependent manner [18, 34]. In our
model, magnesium was able to restore BGP-induced cell
damage, which was reﬂected in reduced apoptosis and
stimulation of cell proliferation. It has been shown that
magnesium has in part calcimimetic actions in terms of
stimulation of the calcium-sensing receptor (CaSR) [37].
Molostov et al. [38] could show that the stimulation of
CaSR on VSMCs leads to enhanced cell proliferation and
protects against apoptosis. This is consistent with earlier
experiments with rat VSMCs, in which magnesium in-
creased cell viability and proliferation, when added at con-
centrations of 2–4 mM [39]. Furthermore, it could be
shown that the stimulation of CaSR with calcimimetics
reduced mineral deposition in VSMCs [40]. This suggests
that magnesium in our experimental model might inhibit
apoptosis and enhance cell viability possibly at least in part
via its calcimimetic action on the CaSR. As apoptosis was
reported to initiate calciﬁcation [18] and inhibition of apop-
tosis reduced calciﬁcation and osteogenic transdifferentia-
tion in experimental settings [18, 26, 34], this inhibitory
effect of magnesium on apoptosis may be responsible for
inhibiting the inappropriate osteogenic transdifferentiation
of VSMCs induced by high phosphate levels and seem to
be one part of the inhibitory mechanism of magnesium on
BVSMC calciﬁcation observed in our studies.
It has been suggested that the effect of magnesium on
VC and atherosclerosis may be mediated via competition
with calcium for cell entry [41–43]. Calcium channels are
the main entry mechanism for calcium into VSMCs as well
as into matrix vesicles and play an important role in calci-
ﬁcation of VSMCs [44]. Despite not being true for all
blockers tested, inhibition of calcium channels have been
shown to inhibit calciﬁcation [45, 46]. Futhermore, there
are several in vitro studies showing inhibitory action of
elevated magnesium concentration on different types
of calcium channels in VSMCs as well as other cell types
of the cardiovascular system [47–49]. Our results conﬁrm
these ﬁndings in BVSMCs by showing that calcium entry
seems to be inhibited at higher magnesium concentrations
while simultaneously magnesium uptake is increased. Re-
cently, it has been proposed that two members of the tran-
sient receptor potential (TRP) ion channel family, TRPM6
and TRPM7, play important roles in magnesium handling.
In addition, these channels are permeable for calcium ions
thereby regulating calcium homoeostasis and they are
expressed on VSMCs [50–53]. Furthermore, crosstalk
between members of the calcium-channel family of annex-
ins, also involved in calcium entry in matrix vesicles, and
Transient receptor potential cation channel subfamily M
members (TRPMs) have been shown [54]. So magnesium
may also via TRPM7 inﬂuence calcium uptake into the
cells as well as into matrix vesicles and therefore seems
to be involved in mediating the inhibitory effect of magne-
sium on calciﬁcation in our cell culture model. Very
recently, indeed, a role of TRPM7 in mediating effect of
magnesium on calciﬁcation could be conﬁrmed [55].
Furthermore, it was shown that elevated calcium is able
to up-regulate the phosphate transporter Pit-1, which in
turn via an elevated phosphate uptake, leads by induction
of CBFA1 to transdifferentiation of VSMCs [56]. There-
fore, lowering the calcium load of the cells might, in addi-
tion to the mechanisms discussed above, may also be one
aspect of inhibiting the transdifferentiation into osteoblast-
like cells. Of course, these hypotheses are speculative
and have to be conﬁrmed in further studies to clarify the
role of these channels in the inhibitory effect of magnesium
on VC.
As a conclusion, higher magnesium levels prevented
calciﬁcation and further progression of already established
calciﬁcation in BVSMCs and further progression of already
established calciﬁcation. In addition to the deposition of
calcium, osteogenic transdifferentiation was inhibited by
elevated magnesium concentrations. Increase in MGP
levels, alterations in cell viability and apoptosis as well
as inhibition of calcium entry into the cells may be partly
involved in mediating this effect. However, the exact
mechanism by which magnesium acts on this process needs
to be further clariﬁed. These results are in concordance with
experimental animal studies as well as with clinical studies
linking elevated magnesium levels to beneﬁcial effects on
VC and mortality [5–10, 19–21]. Thus, magnesium seems
to inﬂuence molecular processes associated with VC and it
may be prudent to more carefully observe serum magne-
sium levels also in patients suffering from renal failure in
order to detect a possible protective effect of this mineral
against VC also in clinical situations. Controlled interven-
tional studies are, however, needed to better understand its
role.
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Abstract
Background. Thiosulfate has been shown to inhibit vas-
cular calciﬁcation in uremic rats and may inhibit calciﬁca-
tion in humans with end-stage renal disease but whether
this is due to a systemic or local action is unknown. The
underlying mechanism is also unclear but complexation of
calcium ions has been proposed.
Methods. In vitro assays were used to determine the effect
of thiosulfate on vascular calciﬁcation and hydroxyapatite
formation.
Results. Thiosulfate (EC50: 1–2 mM) prevented calciﬁca-
tion of injured or devitalized aortas but not uninjured aor-
tas, and similar results were obtained with sulfate. There
was no effect on reversal of calciﬁcation. Measurements
with an ion-sensitive electrode (corrected for changes in
ionic strength) revealed a very weak interaction between
thiosulfate and Ca
21 (Ka ¼ 10.9 6 1.0 3 10
 6 M
 1) that
resulted in a 4% decrease in ionized Ca
21 in culture me-
dium at 5 mM thiosulfate and a corresponding 5% increase
in the solubility product for calcium–phosphate. Adjust-
ment of the total Ca
21 concentration to account for this
did not prevent the inhibition of aortic calciﬁcation by thi-
osulfate. Thiosulfate did not inhibit hydroxyapatite forma-
tion from seed crystals or the calciﬁcation of puriﬁed
elastin and did not alter medium pH.
Conclusions. Thiosulfate inhibits vascular calciﬁcation at
millimolar concentrations through a direct extracellular ef-
fect that does not require intact smooth muscle cells but is
related to cellular injury. This effect is not speciﬁc for
thiosulfate since sulfate has similar properties. Inhibition
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